Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Share-based Compensation (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Share-based Compensation for 3 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 398.54% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Dec 2025, up 408.8% year-over-year, with the annual reading at $10.7 million for FY2025, 408.8% up from the prior year.
  • Share-based Compensation hit $9.5 million in Q4 2025 for Mangoceuticals, up from $1.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $9.5 million in Q4 2025 to a low of $37965.0 in Q1 2024.
  • Historically, Share-based Compensation has averaged $1.1 million across 3 years, with a median of $65556.5 in 2023.
  • Biggest five-year swings in Share-based Compensation: plummeted 40.93% in 2024 and later soared 911.23% in 2025.
  • Year by year, Share-based Compensation stood at $429079.0 in 2023, then soared by 344.8% to $1.9 million in 2024, then soared by 398.54% to $9.5 million in 2025.
  • Business Quant data shows Share-based Compensation for MGRX at $9.5 million in Q4 2025, $1.1 million in Q3 2025, and $50979.0 in Q2 2025.